Is Bristol-Myers Squibb Company (BMY) overvalued? · P/E 17, rev $48.19B
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
This page asks whether Bristol-Myers Squibb Company (BMY) looks expensive on cached numbers — not a short thesis.
Latest reported BMY revenue for 2025-12-31 was $48.19B. Net income was $7.05B. Revenue was down 0.2% from 2024-12-31 to 2025-12-31. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BMY 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BMY stock page for the full model, not this heading.
Not investment advice.